Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 22Neoplasms, Plasma Cell 2Renal Insufficiency 1Recurrence 1Kidney Failure, Chronic 1

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × belantamab mafodotin × Clear all
NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Wake Forest University Health Sciences

Phase 1/2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

University of Pennsylvania

Phase 2 Active not recruiting
41 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡